PR83542

COLUMBUS, Ohio, April 2, 2020 /PRNewswire=KYODO JBN/ --

CAS, a division of the American Chemical Society specializing in scientific

information solutions, is partnering with research and technology organizations

worldwide to tackle the complex challenges presented by COVID-19. In support of

calls to action from the White House Office of Science and Technology Policy

and innovation leaders around the globe, CAS just released an open accessdataset

(https://c212.net/c/link/?t=0&l=en&o=2766637-1&h=2806644639&u=https%3A%2F%2Fwww.cas.org%2Fcovid-19-antiviral-compounds-dataset&a=open+access+dataset ) of chemical compounds with known or potential

antiviral activity to support research, data mining and analytics applications.

Logo - https://mma.prnewswire.com/media/1029755/CAS_Logo.jpg

The new CAS COVID-19 Antiviral Candidate Compounds Dataset contains nearly

50,000 chemical substances assembled from the CAS REGISTRY(R) that have

antiviral activity reported in published literature or are structurally similar

to known antivirals. Related metadata, such as CAS Registry Number(R), physical

properties and a connection table for each substance, are also provided. The

dataset is the first chemical substance collection contributed to the Allen

Institute for AI's COVID-19 Open Research Dataset "CORD-19" and can also be

downloaded directly from CAS.

"I am deeply appreciative of the researchers and healthcare professionals on

the front lines of the fight against COVID-19. CAS is fully committed to

leveraging our content, technology and expertise in every way possible to

support them in overcoming this challenge and saving lives," says Manuel

Guzman, CAS President. "This initial dataset, curated by our team of

scientists, will enable researchers, as well as emerging technologies such as

AI, to make novel connections between previously published chemical research to

hopefully accelerate treatments for this disease. We welcome inquiries from

project teams that would benefit from contributions of additional data or

services to support COVID-19 efforts."

As routine availability of an approved vaccine for COVID-19 is likely more than

a year away, much of the short-term therapeutic research focus is on antiviral

therapies that can mitigate symptoms and speed recovery. The curated collection

of known and potential antiviral compounds CAS has developed provides a pool of

candidate molecules that, if proven active against COVID-19, could be

repurposed as short-term treatments.

 About CAS CAS, a division of the American Chemical Society specializing in scientific

information solutions, partners with R&D organizations globally to provide actionable

insights that help them plan, innovate, protect their innovations, and predict how

new markets and opportunities will evolve. Scientific researchers, patent professionals

and business leaders around the world across commercial, academic and government

sectors rely on our solutions and services to advise discovery and strategy. Leverage our

unparalleled content, specialized technology, and unmatched human expertise to customize solutions that will give your organization an information advantage. With more than 110 years'

experience, no one knows more about scientific information than CAS.

Learn more at www.cas.org.

Media Contact:

Tina Tomeo

cas-pr@cas.org

SOURCE: CAS